David Gray has been involved in clinical drug development in the pharmaceutical and biotechnology industries for over twenty-five years including leadership positions in clinical operations and biostatistics. He feels fortunate to have participated in the development and approval of life-changing therapies including an aerosol antibiotic for cystic fibrosis and a targeted antibody drug conjugate for Hodgkin and T-cell lymphomas.
He is now a consultant based in Seattle working with companies and other organizations pursuing oncology research and drug development from translation through regulatory approval. In addition to serving on the Board of Directors of GRACE he also serves on the Board of CRAB, Cancer Research, and Biostatistics, and looks forward to finding opportunities to support other medical research and healthcare nonprofits. He has an MBA from the Wharton School at the University of Pennsylvania and a Ph.D. in Statistics from the University of Kentucky.